CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Hagens Berman has opened an investigation into Capricor Therapeutics following a 64% stock collapse on July 27, 2026. The FDA's briefing document revealed that the company's lead drug candidate Deramiocel failed to meet pre-specified primary and secondary efficacy endpoints in the Phase 3 HOPE-3 trial, contradicting Capricor's December 2025 announcement of 'positive' results. The investigation focuses on whether Capricor misled investors about trial efficacy and undisclosed changes to the statistical analysis plan.